{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,23]],"date-time":"2026-01-23T08:50:14Z","timestamp":1769158214038,"version":"3.49.0"},"reference-count":44,"publisher":"Elsevier BV","issue":"11-12","license":[{"start":{"date-parts":[[2010,6,1]],"date-time":"2010-06-01T00:00:00Z","timestamp":1275350400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2010,6,1]],"date-time":"2010-06-01T00:00:00Z","timestamp":1275350400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["bmn.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Drug Discovery Today"],"published-print":{"date-parts":[[2010,6]]},"DOI":"10.1016\/j.drudis.2010.04.006","type":"journal-article","created":{"date-parts":[[2010,5,6]],"date-time":"2010-05-06T06:01:04Z","timestamp":1273125664000},"page":"468-473","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"title":["Light-activated antibodies in the fight against primary and metastatic cancer"],"prefix":"10.1016","volume":"15","author":[{"given":"Stephen","family":"Thompson","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexander C.","family":"Self","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Colin H.","family":"Self","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.drudis.2010.04.006_bib1","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1038\/nrc2394","article-title":"Paul Ehrlichs magic bullet concept: 100 years of progress","volume":"8","author":"Strebhardt","year":"2008","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.drudis.2010.04.006_bib2","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1016\/S1359-6446(03)02714-4","article-title":"Renaissance of cancer therapeutic antibodies","volume":"8","author":"Glennie","year":"2003","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.drudis.2010.04.006_bib3","doi-asserted-by":"crossref","first-page":"1774","DOI":"10.1200\/JCO.2007.15.7438","article-title":"Monoclonal antibodies in cancer therapy: 25 years of progress","volume":"26","author":"Oldham","year":"2008","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.drudis.2010.04.006_bib4","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1038\/nrd2241","article-title":"Developmental trends for monoclonal antibody cancer therapeutics","volume":"6","author":"Reichert","year":"2007","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.drudis.2010.04.006_bib5","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/S0169-409X(01)00227-7","article-title":"Targeted drug conjugates: principles and progress","volume":"53","author":"Garnett","year":"2001","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.drudis.2010.04.006_bib6","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.1158\/1535-7163.1493.3.11","article-title":"Biological impediments to monoclonal antibody-based cancer immunotherapy","volume":"3","author":"Christiansen","year":"2004","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.drudis.2010.04.006_bib7","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1021\/bc050137k","article-title":"Biodegradable nanoparticles for direct or two-step tumour immunotargeting","volume":"17","author":"Nobs","year":"2006","journal-title":"Bioconjug. Chem."},{"key":"10.1016\/j.drudis.2010.04.006_bib8","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1016\/S0140-6736(06)68396-7","article-title":"How specific are therapeutic monoclonal antibodies","volume":"367","author":"Self","year":"2006","journal-title":"Lancet"},{"key":"10.1016\/j.drudis.2010.04.006_bib9","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1038\/nrc1913","article-title":"Comparing antibody and small molecule therapies for cancer","volume":"6","author":"Imai","year":"2006","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.drudis.2010.04.006_bib10","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1038\/nrd1957","article-title":"Antibody targeted drugs as cancer therapeutics","volume":"5","author":"Schrama","year":"2006","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.drudis.2010.04.006_bib11","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1007\/s00253-006-0810-y","article-title":"Recombinant therapeutic antibodies","volume":"74","author":"Dubel","year":"2007","journal-title":"Appl. Microbiol. Biotechnol."},{"key":"10.1016\/j.drudis.2010.04.006_bib12","first-page":"413","article-title":"Bispecific antibodies for polyclonal T-cell engagement","volume":"5","author":"Baeuerle","year":"2003","journal-title":"Curr. Opin. Mol. Ther."},{"key":"10.1016\/j.drudis.2010.04.006_bib13","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/S0921-4410(04)22013-0","article-title":"Retargeting T cells and immune effector cells with bispecific antibodies","volume":"22","author":"Lum","year":"2005","journal-title":"Cancer Chemother. Biol. Response Modif."},{"key":"10.1016\/j.drudis.2010.04.006_bib14","doi-asserted-by":"crossref","first-page":"1777","DOI":"10.1517\/14712598.4.11.1777","article-title":"Antibody-directed enzyme prodrug therapy (ADEPT) for cancer","volume":"4","author":"Bagshawe","year":"2004","journal-title":"Expert Opin. Biol. Ther."},{"key":"10.1016\/j.drudis.2010.04.006_bib15","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/S0022-1759(00)00339-2","article-title":"Bispecific human IgG by design","volume":"248","author":"Carter","year":"2001","journal-title":"J. Immunol. Methods"},{"key":"10.1016\/j.drudis.2010.04.006_bib16","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/S0022-1759(00)00342-2","article-title":"Design and application of diabodies, triabodies and tetrabodies for cancer targeting","volume":"248","author":"Todorovska","year":"2001","journal-title":"J. Immunol. Methods"},{"key":"10.1016\/j.drudis.2010.04.006_bib17","doi-asserted-by":"crossref","first-page":"1859","DOI":"10.1158\/1078-0432.CCR-05-2019","article-title":"Enhanced killing of primary ovarian cancer by retargeting autologous cytokine-induced killer cells with bispecific antibodies: a preclinical study","volume":"12","author":"Chan","year":"2006","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.drudis.2010.04.006_bib18","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1007\/s00262-007-0348-6","article-title":"A bispecific diabody directed against prostrate-specific membrane antigen and CD3 induces T-cell mediated lysis of prostate cancer cells","volume":"57","author":"Buhler","year":"2008","journal-title":"Cancer Immunol. Immunother."},{"key":"10.1016\/j.drudis.2010.04.006_bib19","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1007\/s00262-005-0082-x","article-title":"Potent inhibition of local and disseminated tumour growth in immunocompetent mouse models by a bispecific antibody construct specific for murine CD3","volume":"55","author":"Schlereth","year":"2006","journal-title":"Cancer Immunol. Immunother."},{"key":"10.1016\/j.drudis.2010.04.006_bib20","first-page":"53","article-title":"Bi-specific antibody therapy for the treatment of cancer","volume":"3","author":"Withoff","year":"2001","journal-title":"Curr. Opin. Mol. Ther."},{"key":"10.1016\/j.drudis.2010.04.006_bib21","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1038\/440855a","article-title":"Can super-antibody drugs be tamed?","volume":"440","author":"Hopkin","year":"2006","journal-title":"Nature"},{"key":"10.1016\/j.drudis.2010.04.006_bib22","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1007\/s10434-001-0564-9","article-title":"Isolated limb perfusion in the management of patients with recurrent limb melanoma","volume":"8","author":"Thompson","year":"2001","journal-title":"Ann. Surg. Oncol."},{"key":"10.1016\/j.drudis.2010.04.006_bib23","doi-asserted-by":"crossref","first-page":"iv107","DOI":"10.1093\/annonc\/mdh913","article-title":"Regional treatment of metastasis: role of regional perfusion. State of the art isolated limb perfusion for limb salvage","volume":"15","author":"Eggermont","year":"2004","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.drudis.2010.04.006_bib24","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1007\/s101030200040","article-title":"Selective photothermal interaction using an 805-nm diode laser and indocyanine green in gel phantom and chicken breast tissue","volume":"17","author":"Liu","year":"2002","journal-title":"Lasers Med. Sci."},{"key":"10.1016\/j.drudis.2010.04.006_bib25","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1177\/153303460400300104","article-title":"Nanoshell-enabled photonics-based imaging and therapy of cancer","volume":"3","author":"Loo","year":"2004","journal-title":"Technol. Cancer Res. Treat."},{"key":"10.1016\/j.drudis.2010.04.006_bib26","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.canlet.2005.07.035","article-title":"Selective laser photo-thermal therapy of epithelial carcinoma using anti-EGFR antibody conjugated gold nanoparticles","volume":"239","author":"El-Sayed","year":"2006","journal-title":"Cancer Lett."},{"key":"10.1016\/j.drudis.2010.04.006_bib27","doi-asserted-by":"crossref","first-page":"1730","DOI":"10.1158\/1535-7163.MCT-08-0016","article-title":"In vitro and in vivo targeting of hollow gold nanoshells directed at epidermal growth factor receptors for photoablation therapy","volume":"7","author":"Melancon","year":"2008","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.drudis.2010.04.006_bib28","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1007\/s11060-007-9467-3","article-title":"Immunonanoshells for targeted photothermal ablation in medulloblastoma and glioma: an in vitro evaluation using human cell lines","volume":"86","author":"Bernardi","year":"2008","journal-title":"J. Neurooncol."},{"key":"10.1016\/j.drudis.2010.04.006_bib29","doi-asserted-by":"crossref","first-page":"1442","DOI":"10.1038\/sj.bjc.6602517","article-title":"The development and characterisation of porphorin isothiocyanate-monoclonal antibody conjugates for photoimmunotherapy","volume":"92","author":"Hudson","year":"2005","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.drudis.2010.04.006_bib30","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1517\/17425247.4.2.131","article-title":"Photodynamic therapy and cancer: a brief sightseeing tour","volume":"4","author":"Palumbo","year":"2007","journal-title":"Expert Opin. Drug Deliv."},{"key":"10.1016\/j.drudis.2010.04.006_bib31","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1007\/s12094-008-0172-2","article-title":"Photodynamic therapy of cancer: basic principles and applications","volume":"10","author":"Juarranz","year":"2008","journal-title":"Clin. Trans. Oncol."},{"key":"10.1016\/j.drudis.2010.04.006_bib32","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/bjp.2008.98","article-title":"Photodynamic therapy: novel third generation photosensitizers one step closer?","volume":"154","author":"Josefsen","year":"2008","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.drudis.2010.04.006_bib33","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1006\/bbrc.1994.1834","article-title":"Photocleavable nitrobenyl-protein conjugates","volume":"201","author":"Thompson","year":"1994","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.drudis.2010.04.006_bib34","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1038\/nm0796-817","article-title":"Light activatable antibodies: models for remotely activatable proteins","volume":"2","author":"Self","year":"1996","journal-title":"Nat. Med."},{"key":"10.1016\/j.drudis.2010.04.006_bib35","doi-asserted-by":"crossref","first-page":"1587","DOI":"10.1002\/cmdc.200700200","article-title":"Light directed activation of human T-cells","volume":"2","author":"Self","year":"2007","journal-title":"ChemMedChem"},{"key":"10.1016\/j.drudis.2010.04.006_bib36","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1016\/j.bbrc.2007.11.158","article-title":"The construction and in vitro testing of photo-activatable cancer targeting folated anti-CD3 conjugates","volume":"366","author":"Thompson","year":"2008","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.drudis.2010.04.006_bib37","doi-asserted-by":"crossref","first-page":"348","DOI":"10.4161\/mabs.1.4.9045","article-title":"Preclinical evaluation of light-activatable, bispecific antihuman CD3 antibody conjugates as anti-ovarian cancer therapeutics","volume":"1","author":"Thompson","year":"2009","journal-title":"mAbs"},{"key":"10.1016\/j.drudis.2010.04.006_bib38","doi-asserted-by":"crossref","first-page":"1591","DOI":"10.1002\/cmdc.200700116","article-title":"Light activation of anti-CD3 in vivo reduces the growth of an aggressive ovarian carcinoma","volume":"2","author":"Thompson","year":"2007","journal-title":"ChemMedChem"},{"key":"10.1016\/j.drudis.2010.04.006_bib39","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1128\/AAC.40.2.470","article-title":"Selective cytotoxicity of Ricin A chain immunotoxins towards murine cytomegalovirus-infected cells","volume":"40","author":"Barnett","year":"1996","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.drudis.2010.04.006_bib40","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1016\/S1357-2725(01)00128-5","article-title":"Bioactivities of ricin retained and its immunoreactivity to anti-ricin polyclonal antibodies alleviated through pegylation","volume":"34","author":"Hu","year":"2002","journal-title":"Int. J. Biochem. Cell Biol."},{"key":"10.1016\/j.drudis.2010.04.006_bib41","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1039\/b515146e","article-title":"A simple procedure for the photoregulation of chymotrypsin activity","volume":"5","author":"Thompson","year":"2006","journal-title":"Photochem. Photobiol. Sci."},{"key":"10.1016\/j.drudis.2010.04.006_bib42","doi-asserted-by":"crossref","first-page":"1162","DOI":"10.1002\/cmdc.200700078","article-title":"The construction of a functional photoactivatable cancer targeting bispecific antibody conjugate","volume":"2","author":"Thompson","year":"2007","journal-title":"ChemMedChem"},{"key":"10.1016\/j.drudis.2010.04.006_bib43","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1016\/j.addr.2004.01.006","article-title":"Folate mediated targeting of T-cells to tumours","volume":"56","author":"Roy","year":"2004","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.drudis.2010.04.006_bib44","doi-asserted-by":"crossref","first-page":"1839","DOI":"10.1038\/sj.bjc.6603792","article-title":"CD8+ T cell-mediated control of distant tumours following local photodynamic therapy is independent of CD4+ T cells and dependent on natural killer cells","volume":"96","author":"Kabingu","year":"2007","journal-title":"Br. J. Cancer"}],"container-title":["Drug Discovery Today"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1359644610001492?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1359644610001492?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,23]],"date-time":"2025-10-23T12:06:57Z","timestamp":1761221217000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1359644610001492"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,6]]},"references-count":44,"journal-issue":{"issue":"11-12","published-print":{"date-parts":[[2010,6]]}},"alternative-id":["S1359644610001492"],"URL":"https:\/\/doi.org\/10.1016\/j.drudis.2010.04.006","relation":{},"ISSN":["1359-6446"],"issn-type":[{"value":"1359-6446","type":"print"}],"subject":[],"published":{"date-parts":[[2010,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Light-activated antibodies in the fight against primary and metastatic cancer","name":"articletitle","label":"Article Title"},{"value":"Drug Discovery Today","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.drudis.2010.04.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2010 Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}